Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

被引：657

作者：

Mavaddat, Nasim ^{[1
]}

Peock, Susan ^{[1
]}

Frost, Debra ^{[1
]}

Ellis, Steve ^{[1
]}

Platte, Radka ^{[1
]}

Fineberg, Elena ^{[1
]}

Evans, D. Gareth ^{[2
]}

Izatt, Louise ^{[3
]}

Eeles, Rosalind A. ^{[4
]}

Adlard, Julian ^{[5
]}

Davidson, Rosemarie ^{[6
]}

Eccles, Diana ^{[7
]}

Cole, Trevor ^{[8
]}

Cook, Jackie ^{[9
]}

Brewer, Carole ^{[10
]}

Tischkowitz, Marc ^{[11
]}

Douglas, Fiona ^{[12
]}

Hodgson, Shirley ^{[13
]}

Walker, Lisa ^{[14
]}

Porteous, Mary E. ^{[15
]}

Morrison, Patrick J. ^{[16
]}

Side, Lucy E. ^{[17
]}

Kennedy, M. John ^{[18
,19
]}

Houghton, Catherine ^{[20
]}

Donaldson, Alan ^{[21
]}

Rogers, Mark T. ^{[22
]}

Dorkins, Huw ^{[23
]}

Miedzybrodzka, Zosia ^{[24
,25
]}

Gregory, Helen ^{[24
,25
]}

Eason, Jacqueline ^{[26
]}

Barwell, Julian ^{[27
]}

McCann, Emma ^{[28
]}

Murray, Alex ^{[28
]}

Antoniou, Antonis C. ^{[1
]}

Easton, Douglas F. ^{[1
]}

机构：

[1] Cent Manchester Univ Hosp NHS Fdn Trust, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Manchester, Lancs, England

[2] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[3] Guys Hosp, South East Thames Reg Genet Serv, London SE1 9RT, England

[4] Inst Canc Res & Royal Marsden NHS Fdn Trust, Oncogenet Team, London, England

[5] Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England

[6] Yorkhill Hosp, Ferguson Smith Ctr Clin Genet, Glasgow, Lanark, Scotland

[7] Princess Anne Hosp, Wessex Clin Genet Serv, Southampton, Hants, England

[8] Birmingham Womens Hosp Healthcare NHS Trust, West Midlands Reg Genet Serv, Birmingham, W Midlands, England

[9] Sheffield Childrens Hosp, Sheffield Clin Genet Serv, Sheffield, S Yorkshire, England

[10] Royal Devon & Exeter Hosp, Dept Clin Genet, Exeter EX2 5DW, Devon, England

[11] Addenbrookes Hosp, East Anglian Reg Genet Serv, Dept Clin Genet, Cambridge, England

[12] Newcastle Tyne Hosp NHS Trust, Ctr Life, Inst Med Genet, Newcastle Upon Tyne, Tyne & Wear, England

[13] St Georges Univ London, Dept Clin Genet, London, England

[14] Churchill Hosp, Oxford Reg Genet Serv, Oxford OX3 7LJ, England

[15] Western Gen Hosp, South East Scotland Reg Genet Serv, Edinburgh EH4 2XU, Midlothian, Scotland

[16] Belfast City Hosp, Northern Ireland Reg Genet Ctr, Belfast BT9 7AD, Antrim, North Ireland

[17] Great Ormond St Hosp Sick Children, North East Thames Reg Genet Serv, London WC1N 3JH, England

[18] Trinity Coll Dublin, Acad Unit Clin & Mol Oncol, Dublin, Ireland

[19] St James Hosp, Dublin, Ireland

[20] Liverpool Womens NHS Fdn Trust, Cheshire & Merseyside Clin Genet Serv, Liverpool, Merseyside, England

[21] South West Reg Genet Serv, Bristol, Avon, England

[22] Univ Wales Hosp, All Wales Med Genet Serv, Cardiff CF4 4XW, S Glam, Wales

[23] Kennedy Galton Ctr, North West Thames Reg Genet Serv, Harrow, Middx, England

[24] NHS Grampian, North Scotland Reg Genet Serv, Aberdeen, Scotland

[25] Univ Aberdeen, Aberdeen, Scotland

[26] Nottingham Univ Hosp NHS Trust, Nottingham Clin Genet Serv, Nottingham, England

[27] Univ Hosp Leicester NHS Trust, Leicestershire Clin Genet Serv, Leicester, Leics, England

[28] Glan Clwyd Gen Hosp, All Wales Med Genet Serv, Rhyl, Wales

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2013年 / 105卷 / 11期

基金：

英国医学研究理事会;

关键词：

REDUCING SALPINGO-OOPHORECTOMY; CONTRALATERAL BREAST-CANCER; SURGICAL ADJUVANT BREAST; BILATERAL PROPHYLACTIC OOPHORECTOMY; ASHKENAZI JEWISH CARRIERS; OVARIAN-CANCER; GENETIC SUSCEPTIBILITY; GERMLINE MUTATIONS; COMMON VARIANTS; FAMILY-HISTORY;

D O I：

10.1093/jnci/djt095

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Reliable estimates of cancer risk are critical for guiding management of BRCA1 and BRCA2 mutation carriers. The aims of this study were to derive penetrance estimates for breast cancer, ovarian cancer, and contralateral breast cancer in a prospective series of mutation carriers and to assess how these risks are modified by common breast cancer susceptibility alleles. Prospective cancer risks were estimated using a cohort of 978 BRCA1 and 909 BRCA2 carriers from the United Kingdom. Nine hundred eighty-eight women had no breast or ovarian cancer diagnosis at baseline, 1509 women were unaffected by ovarian cancer, and 651 had been diagnosed with unilateral breast cancer. Cumulative risks were obtained using KaplanMeier estimates. Associations between cancer risk and covariables of interest were evaluated using Cox regression. All statistical tests were two-sided. The average cumulative risks by age 70 years for BRCA1 carriers were estimated to be 60% (95% confidence interval [CI] 44% to 75%) for breast cancer, 59% (95% CI 43% to 76%) for ovarian cancer, and 83% (95% CI 69% to 94%) for contralateral breast cancer. For BRCA2 carriers, the corresponding risks were 55% (95% CI 41% to 70%) for breast cancer, 16.5% (95% CI 7.5% to 34%) for ovarian cancer, and 62% (95% CI 44% to 79.5%) for contralateral breast cancer. BRCA2 carriers in the highest tertile of risk, defined by the joint genotype distribution of seven single nucleotide polymorphisms associated with breast cancer risk, were at statistically significantly higher risk of developing breast cancer than those in the lowest tertile (hazard ratio 4.1, 95% CI 1.2 to 14.5; P .02). Prospective risk estimates confirm that BRCA1 and BRCA2 carriers are at high risk of developing breast, ovarian, and contralateral breast cancer. Our results confirm findings from retrospective studies that common breast cancer susceptibility alleles in combination are predictive of breast cancer risk for BRCA2 carriers.

引用

页码：812 / 822

页数：11

共 50 条

[31] Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Kotsopoulos, Joanne
Huzarski, Tomasz
Gronwald, Jacek
Singer, Christian F.
Moller, Pal
Lynch, Henry T.
Armel, Susan
Karlan, Beth
Foulkes, William D.
Neuhausen, Susan L.
Senter, Leigha
Tung, Nadine
Weitzel, Jeffrey N.
Eisen, Andrea
Metcalfe, Kelly
Eng, Charis
Pal, Tuya
Evans, Gareth
Sun, Ping
Lubinski, Jan
Narod, Steven A.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (01):
[32] Defining Variations in Survival of BRCA1 and BRCA2 Mutation Carriers
Grann, Victor R.
Parsons, Ramon E.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (14): : 1597 - 1598
[33] Screening and clinical implications for BRCA1 and BRCA2 mutation carriers
Plon, SE
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1998, 3 (04) : 377 - 387
[34] Screening and Clinical Implications for BRCA1 and BRCA2 Mutation Carriers
Sharon E. Plon
Journal of Mammary Gland Biology and Neoplasia, 1998, 3 : 377 - 387
[35] Oral contraceptives and breast cancer risk in BRCA1 and BRCA2 mutation carriers
Jane C. Figueiredo
Robert W. Haile
Jonine L. Bernstein
Current Breast Cancer Reports, 2009, 1 (3) : 139 - 147
[36] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
Milne, Roger L.
Osorio, Ana
Ramon y Cajal, Teresa
Baiget, Montserrat
Lasa, Adriana
Diaz-Rubio, Eduardo
de la Hoya, Miguel
Caldes, Trinidad
Teule, Alex
Lazaro, Conxi
Blanco, Ignacio
Balmana, Judith
Sanchez-Olle, Gessami
Vega, Ana
Blanco, Ana
Chirivella, Isabel
Esteban Cardenosa, Eva
Duran, Mercedes
Velasco, Eladio
Martinez de Duenas, Eduardo
Tejada, Maria-Isabel
Miramar, Maria-Dolores
Calvo, Maria-Teresa
Guillen-Ponce, Carmen
Salazar, Raquel
San Roman, Carlos
Urioste, Miguel
Benitez, Javier
BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 221 - 232
[37] Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
Roger L. Milne
Ana Osorio
Teresa Ramón y Cajal
Montserrat Baiget
Adriana Lasa
Eduardo Diaz-Rubio
Miguel de la Hoya
Trinidad Caldés
Alex Teulé
Conxi Lázaro
Ignacio Blanco
Judith Balmaña
Gessamí Sánchez-Ollé
Ana Vega
Ana Blanco
Isabel Chirivella
Eva Esteban Cardeñosa
Mercedes Durán
Eladio Velasco
Eduardo Martínez de Dueñas
María-Isabel Tejada
María-Dolores Miramar
María-Teresa Calvo
Carmen Guillén-Ponce
Raquel Salazar
Carlos San Román
Miguel Urioste
Javier Benítez
Breast Cancer Research and Treatment, 2010, 119 : 221 - 232
[38] Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review
Li, Xiao
You, Ran
Wang, Xinwei
Liu, Congxin
Xu, Zicheng
Zhou, Jin
Yu, Bin
Xu, Ting
Cai, Hongzhou
Zou, Qing
CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3971 - 3981
[39] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
Leendert H Zaaijer
Helena C van Doorn
Marian J E Mourits
Marc van Beurden
Joanne A de Hullu
Muriel A Adank
Luc R C W van Lonkhuijzen
Hans F A Vasen
Brigitte F M Slangen
Katja N Gaarenstroom
Ronald P Zweemer
Peggy M L H Vencken
Caroline Seynaeve
Mieke Kriege
British Journal of Cancer, 2016, 115 : 1174 - 1178
[40] Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
Zaaijer, Leendert H.
van Doorn, Helena C.
Mourits, Marian J. E.
van Beurden, Marc
de Hullu, Joanne A.
Adank, Muriel A.
van Lonkhuijzen, Luc R. C. W.
Vasen, Hans F. A.
Slangen, Brigitte F. M.
Gaarenstroom, Katja N.
Zweemer, Ronald P.
Vencken, Peggy M. L. H.
Seynaeve, Caroline
Kriege, Mieke
BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1174 - 1178

← 1 2 3 4 5 →